Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Risako Komata

Risako Komata, MD; Kenju Ando, MD, PhD; Akihiko Shimomura, MD, PhD; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan

Kenju Ando

Risako Komata, MD; Kenju Ando, MD, PhD; Akihiko Shimomura, MD, PhD; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan

Akihiko Shimomura

Risako Komata, MD; Kenju Ando, MD, PhD; Akihiko Shimomura, MD, PhD; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan

Chikako Shimizu

Risako Komata, MD; Kenju Ando, MD, PhD; Akihiko Shimomura, MD, PhD; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan